http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-201001262-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate | 2009-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2011-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EA-201001262-A1 |
| titleOfInvention | Katepsin B Inhibitors |
| abstract | The present invention relates to a method of using the compounds of formula (I) to inhibit cathepsin B. Specifically, the compounds of the present invention are useful as therapeutic agents for the treatment of tumor invasion, metastasis, Alzheimer's disease, arthritis, inflammatory diseases such as chronic and acute pancreatitis, inflammatory respiratory disease, disorders of bones and joints, including osteoporosis, osteoarthritis, rheumatoid arthritis, psoriasis and other autoimmune diseases, liver fibrosis, VK Clinical HCV-associated liver fibrosis, all types of steatosis (including non-alcoholic steatohepatitis) and alcohol-related steatohepatitis, non-alcoholic liver obesity, forms of pulmonary fibrosis, including idiopathic pulmonary fibrosis, pathological diagnosis of interstitial pneumonia, pulmonary fibrosis, and pulmonary fibrosis, and fibrosis / gliosis of the eye, scleroderma, and systemic sclerosis. The compounds of formula (I) are also useful in the treatment of mammalian subjects suffering from both HCV and fibrosis, specifically liver fibrosis, and subjects diagnosed with or at risk for both HCV and liver fibrosis. |
| priorityDate | 2008-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 49.